Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rodino-Klapac Louise
Sarepta Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Janus Henderson Group plc(4.6%)
Sarepta Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Capital International Investors(6.7%)
Sarepta Therapeutics | 10-Q: Q3 2024 Earnings Report
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Connelly Deirdre P
Sarepta Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Connelly Deirdre P
Sarepta Therapeutics | 8-K: Current report
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BEHRENS M KATHLEEN
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Estepan Ian Michael
Sarepta Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Chambers Michael Andrew
Sarepta Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Sarepta Therapeutics | 10-Q: Q2 2024 Earnings Report
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BEHRENS M KATHLEEN
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Brown Ryan Edward
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rodino-Klapac Louise
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Murray Dallan
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Estepan Ian Michael
Sarepta Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Arif Bilal
Sarepta Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
No Data
No Data